SynDevRx has offices in Scottsdale Arizona and Cambridge Massachusetts. Our team has decades of oncology drug development expertise. Our goal is to develop novel drug conjugates and commercialize them through partnerships with industry leaders.
Here at SynDevRx, we believe that success comes from a balanced combination of leading technology and talented people with synergistic skills. Our combination of best-in-class technology, a world-class SAB comprised of world Key Opinion Leaders in clinical oncology, a team of senior drug development professionals delivers high value solutions to patients and investors alike.
Lead Drug - SDX-7320
MetAP2 is a unique, clinically recognized target, that has researchers and scientists' attention. It was recently announced that MetAP2 is possibly a newly-defined oncogene, thereby elevating its importance with respect to cancer treatments. Yet, until this generation of technology, finding a suitable compound that safely and selectively targets MetAP2 has proven elusive.
Our technology successfully achieves what no other approach has been able to do - provide highly active MetAP2 inhibition with a wide therapeutic index.
MetAP2 is recognized as a key mediator of many diseases. Our goal is to leverage our technology in multiple markets where there is a high unmet medical need and where MetAP2 is known to be a key player in the disease's progression.